January 7, 2016 11:05am

Next-generation CAR Programs to treat B-Cell Malignancies; KITE also collaborates with the Experimental Transplantation and Immunology Branch and the Surgery Branch of the NCI


 

KITE has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI for the research and clinical development of a fully human anti-CD19 chimeric antigen receptor (CAR) product candidate for the treatment of B-cell lymphomas and leukemias. 

 

Under the CRADA, Kite will collaborate with James (Jim) N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI, to evaluate this product candidate in a P1 clinical study this year.

In addition, the newly established CRADA will focus on the development of next-generation CAR programs directed against other novel antigens for the treatment of B-cell lymphomas and leukemias. 

KITE will also continue to advance multiple CAR and T cell receptor (TCR) programs under its existing CRADA with the Surgery Branch of the NCI, led by Dr. Rosenberg, a recognized pioneer in immuno-oncology and special advisor to Kite.

 

The Bottom Line: The new CRADA could improve the success of CAR therapy for patients with advanced B-cell malignancies.

 

KITE jumped $0.55, slipping to +$0.35 after the 10:30 am release having opened at $57.13